Q-omics provides the consensus-scored RPL26P20 profile across patient tissues and cancer cell-line models. RPL26P20 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RPL26P20 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, RPL26P20 RNA expression shows 6,378 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, LUSC, and STAD as cancer lineages where RPL26P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL26P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL26P20 survival associations across molecular data types. RPL26P20 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL26P20 RNA expression–survival associations across cancer types. High RPL26P20 expression shows unfavorable associations in KICH, ESCA, COAD, ACC and THCA, but favorable associations in UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for RPL26P20 RNA expression.
This table summarizes RPL26P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL26P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL26P20 shows lower tumor expression in LUSC, KICH and COAD. The LUSC box plot shows higher RPL26P20 RNA expression in normal versus tumor tissue (log2 FC = −0.106, t-test p = .002).
This table shows molecular features associated with RPL26P20 in patient tissues and cancer cell lines. In patient samples, RPL26P20 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
